GlassScriptPhysician profile
Mehrdad M Tavallaee
NPI 1689625634
$5,213.45
in general payments reported to CMS, 2019-2025
49 companies · $556 in 2025
The $556 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $242 · 2021: $904 · 2022: $1,034 · 2023: $947 · 2024: $453 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.44 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $602.21 | 2019-2025 | Linzess, Viberzi, Vraylar |
| Astrazeneca Pharmaceuticals LP | $445.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $348.61 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.09 | 2019-2024 | Stiolto Respimat, Ofev |
| Glaxosmithkline, LLC. | $282.83 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $267.27 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $229.13 | 2019-2025 | Wegovy, Ozempic |
| Teva Pharmaceuticals USA, INC. | $216.90 | 2021-2023 | Austedo Xr, Austedo |
| Xeris Pharmaceuticals, INC. | $211.86 | 2021-2024 | Gvoke Hypopen |
| Pfizer INC. | $206.91 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $140.39 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $130.28 | 2022-2025 | Ingrezza |
| Scilex Pharmaceuticals INC. | $128.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $122.81 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.43 | 2021-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehrdad Tavallaee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.